GTS5:Table of Contents: Difference between revisions
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 50: | Line 50: | ||
- [[GTS5:Activated Phosphatidylinositol-3-OH kinase δ Syndrome - APDS (PIK3CD)]] | - [[GTS5:Activated Phosphatidylinositol-3-OH kinase δ Syndrome - APDS (PIK3CD)]] | ||
'''Transcription factors and regulators''' | '''Transcription factors and regulators''' | ||
- [[GTS5:Multiple endocrine neoplasia type 5, MAX related tumours (MAX)]] | - [[GTS5:Multiple endocrine neoplasia type 5, MAX related tumours (MAX)]] | ||
- [[GTS5:MAFA-related familial insulinomatosis (MAFA)]] | - [[GTS5:MAFA-related familial insulinomatosis (MAFA)]] | ||
| Line 60: | Line 59: | ||
==Oxidative stress response and metabolism ([[GTS5:Oxidative stress response and metabolism|Overview Page Link]])== | ==Oxidative stress response and metabolism ([[GTS5:Oxidative stress response and metabolism|Overview Page Link]])== | ||
'''Angiogenesis''' | '''Angiogenesis''' | ||
- [[GTS5:Von Hippel-Lindau syndrome (VHL)]] | - [[GTS5:Von Hippel-Lindau syndrome (VHL)]] | ||
| Line 67: | Line 66: | ||
- [[GTS5:Hereditary leiomyomatosis and renal cell carcinoma syndrome (FH)]] | - [[GTS5:Hereditary leiomyomatosis and renal cell carcinoma syndrome (FH)]] | ||
'''Toxic metabolite-mediated disorders''' | |||
- [[GTS5:Hereditary tyrosinaemia type 1 (FAH)]] | - [[GTS5:Hereditary tyrosinaemia type 1 (FAH)]] | ||